Prof Sven Mahner talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about the phase III HECTOR study.

The study compared carboplatinum and topotecan with well established platinum based regimens, gemcitabin plus carboplatin and paclitaxel-carboplatin in order to compare the efficacy of the two arms.

Topotecan was analysed against the standard treatment based on promising results in phase I and II trials, but the HECTOR study included 550 patients and found the treatment did not meet the primary endpoint of improving one year overall survival.

Filming supported by Amgen